The intriguing possibility that altering the microbiome might offer a way of augmenting response to immunotherapy is one of the pioneering new treatment options being explored in oncology.
TAT 2020 Honorary Award recipient Lillian L. Siu, Professor at the University of Toronto and Medical Oncologist at the Princess Margaret Cancer Centre, Toronto, explains the latest progress being made in using ‘bugs as drugs’.
PROfound study shows benefit in radiological progression-free survival with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant prostate cancer
Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer
Targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy
Many studies presented at the Congress hint at promising treatments for rare sarcomas but access to effective treatments remains a challenge
Results from TAILORx trial presented at ESMO 2019
PROs encourage patient-centred cancer care
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
